Registry for TFE Renal Cell Carcinoma patients
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
This study is creating a detailed registry for people with TFE Renal Cell Carcinoma to collect important health information and samples that will help researchers learn more about the disease and how to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Children's Hospital Medical Center, Cincinnati Academic / other |
| Locations | 1 site (Cincinnati, Ohio) |
| Trial ID | NCT03630536 on ClinicalTrials.gov |
What this trial studies
This initiative aims to create a comprehensive registry for patients diagnosed with TFE Renal Cell Carcinoma (RCC) to gather clinical, demographic, and pathological data, along with biological specimens. The registry will facilitate the collection of imaging and treatment data, enabling researchers to better understand the biology and treatment responses of TFE RCC. Patients will be identified through existing cancer registries, clinician referrals, or direct contact with registry staff. The collected data will be securely stored and may be used for future translational research.
Who should consider this trial
Good fit: Ideal candidates include patients of any age with a suspected or confirmed diagnosis of TFE Renal Cell Carcinoma.
Not a fit: Patients who do not have a diagnosis of TFE Renal Cell Carcinoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of TFE RCC, leading to improved treatment strategies and outcomes for patients.
How similar studies have performed: While there is limited data specifically on TFE RCC, similar registries for other cancer types have shown success in advancing understanding and treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients of any age with a suspected diagnosis or confirmed diagnosis of a TFE Renal Cell Carcinoma. * Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent. Exclusion Criteria: * Any patient that has not been diagnosed with TFE Renal Cell Carcinoma
Where this trial is running
Cincinnati, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: James Geller, MD — Children's Hospital Medical Center, Cincinnati
- Study coordinator: Site Public Contact
- Email: TRRI@cchmc.org
- Phone: (844) 722-8774
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.